Funny how Victoza gets approved in Europe whereas Byetta has hardly ever been marketed in Europe (well not much by Lilly anyways). I don't see much point in trying to market the heck out of Byetta in Europe either if Victoza gets itself established. Victoza has better efficacy, more or less, 1x a day shot, vs. 2x a day Byetta BID.
Interesting how one drug may come to dominate one market and the other the other market. Byetta sold like pancakes for its first few years on the market, will not Victoza sell like pancakes in Europe in its first few years?
Tinker
Market Data 
Markets 
AI
